evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

238 questions · 242 findings · 21 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 37 · 15.3%GRADE not reported 15 · 6.2%Very low 78 · 32.2%Low 52 · 21.5%Moderate 49 · 20.2%High 11 · 4.5%

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Satisfaction with care: Loss to · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes satisfaction with care: Loss to compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (very low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Weight (kg) · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
2 findings from 1 review

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether levomepromazine changes leaving the study early ‐ short term ‐ due to lack of efficacy compared with atypical antipsychotics (very low certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ due to patient deterioration · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to patient deterioration compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ lost to · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ lost to compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Withdrawals due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review